Indeed, some studies report lower incidences of CV events in RA patients following tofacitinib treatment [11,12], while a recent metanalysis describes an increased risk of MACE with tofacitinib use in subjects with certain CV risk factors and aged older than 65, as compared to anti-TNF treatment [13]. The gene discussed is TNF; the disease is rheumatoid arthritis.